Boston Scientific Corporation | Large-cap | Healthcare
$104.78
-2.45%
| Boston Scientific Stock Comparison:
Boston Scientific vs Abbott LaboratoriesBoston Scientific vs StrykerBoston Scientific vs Medtronic plcBoston Scientific vs Edwards LifesciencesBoston Scientific vs DexcomBoston Scientific vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 16.7B
Gross Profit 11.5B 68.61%
Operating Income 3.0B 17.93%
Net Income 1.8B 11.02%
EPS (Diluted) $1.25

Balance Sheet Metrics

Total Assets 39.4B
Total Liabilities 17.4B
Shareholders Equity 22.0B
Debt to Equity 0.79

Cash Flow Metrics

Operating Cash Flow 3.0B
Free Cash Flow 2.4B

Revenue & Profitability Trend

Boston Scientific Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 16.7B 14.2B 12.7B 11.9B 9.9B
Cost of Goods Sold 5.3B 4.3B 4.0B 3.7B 3.5B
Gross Profit 11.5B 9.9B 8.7B 8.2B 6.4B
Research & Development 1.6B 1.4B 1.3B 1.2B 1.1B
Selling, General & Administrative 6.0B 5.2B 4.5B 4.4B 3.8B
Other Operating Expenses 889.0M 874.0M 850.0M 790.0M 789.0M
Total Operating Expenses 8.5B 7.5B 6.7B 6.4B 5.7B
Operating Income 3.0B 2.4B 2.0B 1.8B 684.0M
Pre-tax Income 2.3B 2.0B 1.1B 1.1B -79.0M
Income Tax 436.0M 393.0M 443.0M 36.0M 2.0M
Net Income 1.8B 1.6B 698.0M 1.0B -82.0M
EPS (Diluted) $1.25 $1.07 $0.45 $0.69 -$0.12

Income Statement Trend

Boston Scientific Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 6.9B 6.5B 5.8B 6.3B 6.7B
Non-Current Assets 32.5B 28.6B 26.7B 25.9B 24.1B
Total Assets 39.4B 35.1B 32.5B 32.2B 30.8B
Liabilities
Current Liabilities 6.4B 4.9B 3.8B 4.3B 3.7B
Non-Current Liabilities 11.0B 10.7B 11.1B 11.3B 11.8B
Total Liabilities 17.4B 15.6B 14.9B 15.6B 15.5B
Equity
Total Shareholders Equity 22.0B 19.5B 17.6B 16.6B 15.3B

Balance Sheet Composition

Boston Scientific Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 1.8B 1.6B 698.0M 1.0B -82.0M
Operating Cash Flow 3.0B 2.4B 1.2B 1.8B 1.2B
Investing Activities
Capital Expenditures -787.0M -707.0M -576.0M -540.0M -364.0M
Investing Cash Flow -5.4B -2.5B -2.1B -2.0B -411.0M
Financing Activities
Dividends Paid 0 -28.0M -55.0M -55.0M -28.0M
Financing Cash Flow 1.2B -125.0M 2.4B -155.0M -5.3B
Free Cash Flow 2.4B 1.7B 914.0M 1.3B 1.1B

Cash Flow Trend

Boston Scientific Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 73.94
Forward P/E 36.31
Price to Book 6.75
Price to Sales 8.54
PEG Ratio 36.31

Profitability Ratios

Profit Margin 11.58%
Operating Margin 20.09%
Return on Equity 9.50%
Return on Assets 5.28%

Financial Health

Current Ratio 1.45
Debt to Equity 52.16
Beta 0.69

Per Share Data

EPS (TTM) $1.37
Book Value per Share $15.02
Revenue per Share $11.91

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
bsx 149.9B 73.94 6.75 9.50% 11.58% 52.16
Abbott Laboratories 231.9B 17.31 4.75 30.65% 31.89% 27.09
Stryker 148.0B 52.39 7.07 14.26% 12.31% 82.92
Medtronic plc 110.3B 23.84 2.30 9.51% 13.90% 61.39
Edwards Lifesciences 43.3B 30.51 4.27 16.51% 75.71% 6.86
Dexcom 31.3B 60.03 13.81 23.72% 12.90% 113.97

Financial data is updated regularly. All figures are in the company's reporting currency.